VAXXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:46):

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States...

Stats
本日の出来高	776 416
平均出来高	725 129
時価総額	16.16M
EPS	$0 ( 2024-03-25 )
次の収益日	( $-0.100 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.280
ATR14	$0.00200 (1.56%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-03	Paula Molina Rene	Buy	0
2023-10-02	Powchik Peter	Buy	159 744	Stock option (right to buy)
2023-10-01	Ray Sumita	Buy	0
2023-09-06	Prime Movers Lab Fund I Lp	Sell	5 308	Class A Common Stock
2023-09-07	Prime Movers Lab Fund I Lp	Sell	20 312	Class A Common Stock

INSIDER POWER
49.30
Last 91 transactions
Buy: 5 925 518 \| Sell: 2 685 509

ボリューム相関

長: 0.36 (neutral)

短: 0.00 (neutral)

Signal:(61.842) Neutral

Vaxxinity, Inc. 相関

10 最も正の相関
MEUSW	0.894
VYGR	0.876
ADXN	0.863
LIAN	0.855
IMAB	0.852
WWD	0.85
HSDT	0.849
ICUI	0.848
PXLW	0.845
PRAX	0.84

10 最も負の相関
MTSL	-0.822
EA	-0.815

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Vaxxinity, Inc. 相関 - 通貨/商品

0.00
( neutral )

-0.19
( neutral )

0.00
( neutral )

-0.30
( neutral )

Vaxxinity, Inc. 財務諸表

Annual	2023
収益:	$0
総利益:	$-2.23M (0.00 %)
EPS:	$-0.450

FY	2023
収益:	$0
総利益:	$-2.23M (0.00 %)
EPS:	$-0.450

FY	2022
収益:	$0
総利益:	$-1.68M (0.00 %)
EPS:	$-0.600

FY	2021
収益:	$66 000.00
総利益:	$-1.87M (-2 834.85 %)
EPS:	$-1.100

Financial Reports:

No articles found.

Vaxxinity, Inc.

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.